摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

肌氨酸叔丁酯盐酸盐 | 5616-81-9

中文名称
肌氨酸叔丁酯盐酸盐
中文别名
N-甲基甘氨酸叔丁酯盐酸盐;N-甲基甘氨酸叔丁酯
英文名称
sarcosine tert-butyl ester
英文别名
tert-butyl methylglycinate;tert-butyl 2-(methylamino)acetate;tert-butyl N-methylglycinate;sarcosine t-butyl ester
肌氨酸叔丁酯盐酸盐化学式
CAS
5616-81-9
化学式
C7H15NO2
mdl
MFCD05864597
分子量
145.202
InChiKey
MYKMOIQAHCMLIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    137-141 °C (dec.)
  • 沸点:
    168.5±23.0 °C(Predicted)
  • 密度:
    0.928±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于甲醇(0.3g溶于2mLMeOH)。
  • 稳定性/保质期:

    避免强氧化剂,以免发生不良反应。

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    10
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.857
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • WGK Germany:
    3
  • 安全说明:
    S24/25
  • 危险品运输编号:
    NONH for all modes of transport
  • 海关编码:
    2922499990
  • 包装等级:
    II
  • 危险类别:
    3
  • 危险性防范说明:
    P210,P261,P305+P351+P338
  • 危险性描述:
    H225,H315,H319,H335
  • 储存条件:
    请将药品存放在密闭、阴凉且干燥的地方保存。

SDS

SDS:f25cd237cbe79b91076599e26bf01cc8
查看

制备方法与用途

2-(甲胺基)乙酸叔丁酯是甘酸(HY-Y0966)的衍生物

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    肌氨酸叔丁酯盐酸盐 在 palladium on activated charcoal 氢气N,N'-二环己基碳二亚胺 作用下, 以 甲醇二氯甲烷 为溶剂, -10.0 ℃ 、101.33 kPa 条件下, 反应 2.0h, 生成 N-(benzyloxycarbonyl)-D-valylprolylsarcosine tert-butyl ester
    参考文献:
    名称:
    Toward the Design of an RNA:DNA Hybrid Binding Agent
    摘要:
    One characteristic function of the retroviruses, which is generally not found in normal eukaryotic cells, is production of a long RNA:DNA hybrid in the viral replication phase. If agents are designed which bind only to the RNA:DNA hybrid, but neither to DNA nor to RNA, such agents will be able to inhibit specifically the RNase H activity of retroviral reverse transcriptase, and therefore will suppress viral replication. Actinomycin D binds to double-stranded DNA, but not to RNA, because steric hindrance between the 2-amino group of the phenoxazinone ring and the 2'-hydroxyl group of RNA prevents intercalation of the antibiotic. However, if the C8-H in the phenoxazinone ring is replaced by an aromatic nitrogen N8, a strong hydrogen bond acceptor, this analog (N8-actinomycin D) might be able to bind intercalatively to an RNA:DNA hybrid by forming an additional hydrogen bond between N8 and the 2'-hydroxyl group of guanosine ribose. This hypothesis has been tested by a molecular mechanics calculation using a model structure of the complex between N8-actinomycin D and a small RNA:DNA hybrid, r(GC):d(GC). The results of the molecular mechanics calculation suggest that N8-actinomycin D can intercalatively bind to the RNA: DNA hybrid by making an additional intracomplex hydrogen bond. This hydrogen bonding capability of N8 has been confirmed in the crystal structure of the chromophore of N8-actinomycin D. Thus, N8-actinomycin D has been synthesized by coupling the pyridine and benzene fragments obtained independently. A binding study indicates that both actinomycin D and N8-actinomycin D bind intercalatively not only to DNA:DNA double strands but also to RNA:DNA hybrids. Although the overall binding capacity of N8-actinomycin D is reduced substantially in comparison with that of actinomycin D itself, N8-actinomycin D tends to bind relatively more favorably than actinomycin D to the RNA:DNA hybrids. Thus, this initial attempt at designing an RNA:DNA hybrid binding agent appears to be successful. However, it is necessary to modify the agent further to increase its RNA:DNA hybrid binding character and to decrease the DNA:DNA binding character, in order to make a useful RNA:DNA hybrid binding agent.
    DOI:
    10.1021/ja00085a002
  • 作为产物:
    描述:
    (benzyloxycarbonyl)sarcosine tert-butyl ester 在 palladium on activated charcoal 氢气 作用下, 生成 肌氨酸叔丁酯盐酸盐
    参考文献:
    名称:
    使用新型1 H-苯并咪唑鎓盐高效合成含有N-甲基化氨基酸残基的位阻受阻肽
    摘要:
    设计,合成了新型1 H-苯并咪唑型肽偶联剂CMBI,证明其在促进空间位阻酰胺和酯键形成方面是有效的。通过模型反应试验和成功合成了各种受阻寡肽和含有N-甲基氨基酸残基的肽段,证明了其高效率,其反应速度快,外消旋化程度低且产率高。提出了由试剂介导的酰胺键形成机理。
    DOI:
    10.1016/s0040-4020(00)00963-7
点击查看最新优质反应信息

文献信息

  • [EN] FLAVIN DERIVATIVES<br/>[FR] DÉRIVÉS DE LA FLAVINE
    申请人:BIORELIX PHARMACEUTICALS INC
    公开号:WO2010019208A1
    公开(公告)日:2010-02-18
    The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
    本发明涉及新型黄素衍生物和其他黄素衍生物,它们的用途以及用作核糖开关配体和/或抗感染剂的组合物。该发明还提供了制备新型黄素衍生物的方法。
  • Kappa agonist compounds and pharmaceutical formulations thereof
    申请人:——
    公开号:US20030144272A1
    公开(公告)日:2003-07-31
    Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.
    提供具有kappa阿片受体激动剂活性的化合物,含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA: 1 2 其中 R 1 ,R 2 ,R 3 ,R 4 ;和 X,X 4 ,X 5 ,X 7 ,X 9 ; Y,Z和n如规范中所述。
  • [EN] SULFONAMIDE COMPOUNDS AND THEIR USE AS STAT5 INHIBITORS<br/>[FR] COMPOSÉS DE SULFONAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE STAT5
    申请人:UNIV TORONTO
    公开号:WO2015179956A1
    公开(公告)日:2015-12-03
    The present disclosure relates to compounds having the Formula (Formula (I)) which are inhibitors of STAT5.
    本公开涉及具有化学式(化学式(I))的化合物,这些化合物是STAT5的抑制剂
  • AMIDINE COMPOUND OR SALT THEREOF
    申请人:Tanikawa Tetsuya
    公开号:US20140155597A1
    公开(公告)日:2014-06-05
    The purpose of the present invention is to provide a novel compound which has an anti-fungal activity on pathogenic fungi including fungi belonging to the genus Candida , the genus Aspergillus and the genus Trichophyton and is useful as a medicinal agent. A compound represented by formula (I) (wherein A 1 represents a nitrogen atom or a group represented by formula CR 6 ; A 2 and A 3 are the same as or different from each other and independently represent a nitrogen atom or a group represented by formula CH; R 1 represents an aryl group which may be substituted by 1 to 5 substituents independently selected from a substituent group (2) or the like; R 2 and R 3 are the same as or different from each other and independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 1-6 haloalkyl group or a C 1-6 alkoxy group; and R 4 and R 5 are the same as or different from each other and independently represent a hydrogen atom, a C 1-6 haloalkyl group, a C 1-6 alkyl group or the like) or a salt thereof is useful as an anti-fungal agent.
    本发明的目的是提供一种新颖的化合物,该化合物对包括属于念珠菌属、曲霉属和毛癣菌属的病原真菌具有抗真菌活性,并可用作药物。由公式(I) (其中A 1代表氮原子或由公式CR 6表示的基团;A 2和A 3相同或不同,独立地表示氮原子或由公式CH表示的基团;R 1表示可能由1至5个独立选自取代基组(2)的取代基取代的芳基;R 2和R 3相同或不同,独立地表示氢原子、卤素原子、C 1-6烷基、C 1-6卤代烷基或C 1-6烷氧基;R 4和R 5相同或不同,独立地表示氢原子、C 1-6卤代烷基、C 1-6烷基等)或其盐用作抗真菌剂。
  • Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug
    申请人:Jenkins Thomas E.
    公开号:US20120178773A1
    公开(公告)日:2012-07-12
    The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the \compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
    提供了一种名为KC-7的化合物,N-1-[(S)-2-(氧可酮-6-烯醇-羰基-甲基-基)-2-羰基-肌氨酸-乙胺]-精酸-甘酸-乙酸盐,或其可接受的盐、溶剂化物和合物。本公开还提供了包含前药的组合物及其使用方法,其中组合物包含前药KC-7,该前药能够控制释放氧可酮。这样的组合物可以选择性地提供一种胰蛋白酶抑制剂,该抑制剂与介导前药控制释放氧可酮的酶相互作用,以减弱前药的酶切。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸